Nova Bay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and marketing high-quality, scientifically formulated eye and skin care products, announces record sales of Avenova-branded products at Amazon’s Prime Day event ( July 12-13). Sales of Avenova branded products during the two-day event grew 27% from Prime Days 2021 and 48% from Prime Days 2020, and hit a new all-time high in one day since the product became available on Amazon .com in June 2019.
“We are thrilled to break sales records at this year’s Prime Day event. We believe consumers are feeling the financial pinch of inflation and are looking for great deals on products they regularly buy and use, ” said Justin Hall, CEO of NovaBay. “The exceptionally strong reception of Avenova during Prime Days this year, along with our loyal customer base, gives us even more confidence for continued growth through the important sales channel. Amazon.com. Because dry eye is a chronic problem, we have many lifelong customers.”
In addition to NovaBay’s flagship eye care product, Avenova Lid & Lash Spray, discounts during Prime Days were available on Avenova Lubricant Eye Drops and Avenova Moist Heated Eye Compression Mask. In a first for Prime Days, NovaBay offered Avenova-branded product sets with three different sets available to support eye care for those with bacterial dry eye. Avenova products are highly rated on Amazon.com, with Avenova Lid & Lash Spray receiving 4.5 out of 5 stars from over 11,400 reviews, including 85% ratings of 4 stars or better.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven consumer products for the eye care and skin care markets. Avenova® is the #1 prescribed antimicrobial eyelid and lash spray and DERMAdoctor is a premium skincare brand with over 30 skincare products developed by dermatologists and sold through traditional national retailers , digital beauty chains and international distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information contained in this press release, matters set forth in this press release may be forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the business progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements based on current expectations, assumptions, estimates, projections and forecasts of management. beliefs. These statements include, but are not limited to, statements regarding our business strategies, the impact of Prime Days sales on the company’s overall financial performance, and the company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed or implied by the forward-looking statements. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the most recently filed Forms 10-Q/K and the NovaBay’s registration statement on Filing Form S-1 with the Securities and Exchange Commission, particularly under the heading “Risk Factors.” The forward-looking statements contained in this release speak only as of this date, and NovaBay disclaims any intention or obligation to publicly revise or update any forward-looking statement, except as required by law.
Socialize and stay informed on NovaBay‘s Progress
Like us on Facebook
follow us on Twitter
Connect with NovaBay at LinkedIn
Visit NovaBay’s Website
Avenova purchase information
For NovaBay Avenova purchase information:
Please call 800-890-0329 or email firstname.lastname@example.org
Purchasing information from DERMAdoctor
For DERMAdoctor purchase information:
Please call 877-337-6237 or email email@example.com
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220715005097/en/